24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
ScaleUp House
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
Corporate
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Approval
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
ScaleUp House
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
Corporate
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
12:55
Anthropic’s employee bill hit $1.7 billion in one quarter, or $107,000 per worker each month
12:11
After $30 million in losses, Arkia faces a battle over who will pay for its rescue
12:00
“My biggest concern is that organizations will give agents the ability to act faster and only then develop the ability to govern those actions”
10:20
X and Instagram account for 98% of views of antisemitic content in new study
More stories
Buzz
Most popular
Daily
Weekly
1
From six-person startups to a $6.3 billion take-private: October's extraordinary month for Israeli tech exits
2
ServiceNow CEO says acquired Israeli startup Sweep helps it switch CRM customers in weeks, not years
3
Israeli digital health company TailorMed acquired in $250 million deal
4
Perion to be acquired by India’s Affle for $420 million, marking a steep fall for a once-billion-dollar Israeli company
5
Intel’s Israeli workers fear another downturn after stock collapse and deadly factory blast
More news
Approval
1 stories about Approval
Market Indifferent to European Approval of Teva's Migraine Drug
02.04.19
|
Lilach Baumer
Teva's injection, one of three similar migraine drugs already approved in the U.S., is the third to receive European approval after Amgen Inc. and Novartis AG and Eli Lilly